文献速递颈动脉与弓上血管

优化颈动脉手术患者的二级预防:评估降脂与抗血栓治疗的队列研究

Optimising Secondary Prevention in Patients Undergoing Carotid Surgery: A Cohort Study Assessing Lipid Lowering and Antithrombotic Therapy.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2025-04-06

该单中心队列研究纳入2017年1月1日至2021年12月31日接受颈动脉干预的260例患者,评估围术期指南导向药物治疗处方与LDL-C水平。结果显示入院至出院抗血栓治疗(82% vs. 100%,p < .001)和LLT(88% vs. 94%,p = .004)处方比例显著增加,LDL-C从入院前2.2 mmol/L降至一年随访1.8 mmol/L(p = .026),但仅53%患者达到LDL-C < 1.8 mmol/L目标。

要点

  • 入院至出院抗血栓治疗处方比例从82%升至100%(p < .001),LLT从88%升至94%(p = .004)。
  • 平均LDL-C从入院前2.2 mmol/L降至一年随访1.8 mmol/L(p = .026)。
  • 仅53%患者一年后达到LDL-C < 1.8 mmol/L目标,未达标者均有上调他汀或联用辅助LLT的空间。

核心结论

  • 卒中事件前LLT使用不足被确定为关键的可干预问题。
  • 因颈动脉干预入院与GDMT增加和LDL-C水平降低相关。
  • 存在改善空间,需要长期社区为基础的心血管风险管理,特别是风险评估、LLT启动和持续上调以及LDL-C水平定期监测。

研究设计与样本

  • 单中心队列研究,纳入2017年1月1日至2021年12月31日接受颈动脉干预的260例患者。
  • 查阅电子医院记录获取人口学、合并症、抗血小板和LLT处方及胆固醇结果数据。
  • 获取四个时间点数据:索引事件前、因颈动脉干预入院时、干预后出院时及一年时。

主要发现

  • 索引事件前未使用心脏保护药物的患者中,五分之一有抗血小板治疗指征,39%有高强度LLT指征。
  • 从因颈动脉干预入院至出院,处方抗血栓治疗的患者比例(82% vs. 100%;p < .001)和LLT处方比例(88% vs. 94%;p = .004)统计学显著增加。
  • 平均LDL-C水平从入院前2.2 mmol/L统计学显著降低至一年随访时1.8 mmol/L(p = .026)。
  • 然而,仅53%的患者在干预后一年达到LDL-C < 1.8 mmol/L的目标。
  • 所有未达到LDL-C目标的患者均有上调他汀或联用辅助LLT药物(包括依折麦布、inclisiran和PCSK9i)的空间。

关键数值与推荐

  • 英国和欧洲指南推荐动脉粥样硬化性颈动脉疾病患者应开始最佳心脏保护药物治疗,特别是抗血小板药物和降脂治疗(LLT)。
  • LDL-C目标为 < 1.8 mmol/L。

临床怎么用

  • 因颈动脉干预入院与GDMT增加和LDL-C水平降低相关。
  • 存在改善空间,需要长期社区为基础的心血管风险管理,特别是风险评估、LLT启动和持续上调以及LDL-C水平定期监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: United Kingdom and European guidelines recommend that patients with atherosclerotic carotid artery disease should be commenced on optimal cardioprotective medical therapy, specifically antiplatelet agents and lipid lowering therapy (LLT). This single centre cohort study explored the peri-operative prescription and titration of guideline directed medical therapy (GDMT) alongside low density lipoprotein cholesterol (LDL-C) levels in patients undergoing carotid intervention. METHODS: The study included 260 patients who underwent carotid intervention from 1 January 2017 to 31 December 2021. Electronic hospital records were checked for data on demographics, comorbidities, antiplatelet and LLT prescriptions, and cholesterol results. Data from four time points were obtained: prior to the index event; at the time of admission for carotid intervention; at discharge following intervention; and at one year. RESULTS: Antiplatelet therapy was indicated in one fifth and high intensity LLT in 39% of patients who were not on cardioprotective medications prior to the index event. From the time of admission for carotid intervention to discharge, the proportion of patients who were prescribed antithrombotic therapy (82% vs. 100%; p < .001) and LLT (88% vs. 94%; p = .004) statistically significantly increased. Mean LDL-C levels statistically significantly reduced from 2.2 mmol/L pre-admission to 1.8 mmol/L at one year follow up (p = .026). However, only 53% of patients achieved an LDL-C target of < 1.8 mmol/L one year following intervention. All patients who did not achieve the LDL-C target had scope for uptitration of statin or co-prescription of adjuvant LLT agents, including ezetimibe, inclisiran, and PCSK9i. CONCLUSION: Underutilisation of LLT prior to incident stroke was identified as a key tractable problem. Admission for carotid intervention is associated with an increase in GDMT and reduction in LDL-C levels. There is scope for improvement and a need for long term community based management of cardiovascular risk, specifically risk assessment, initiation and ongoing uptitration of LLT, and regular monitoring of LDL-C levels.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kwan JY, Harper A, Sood M, et al. Optimising Secondary Prevention in Patients Undergoing Carotid Surgery: A Cohort Study Assessing Lipid Lowering and Antithrombotic Therapy. Eur J Vasc Endovasc Surg. 2025. PMID: 40199397. doi:10.1016/j.ejvs.2025.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。